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1 |  INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a disease of 
nearly complete lethality presenting a median survival time 
of 6 months, and is predicted to become the second leading 
cause of cancer- related deaths before 2030.1 This may be ex-
plained by the vast majority of patients presenting with ad-
vanced stages of PDAC at diagnosis, and PDAC cells possess 
a high metastatic potential and are often resistant to available 
cytotoxic drugs.2 Thus, there is an urgent need to identify 
aberrant signaling pathways that present suitable substrates 
for targeted therapies.
Notch signaling is an evolutionarily conserved cell fate 
determination pathway that has great relevance in multiple 
aspects of cancer biology.3 It promotes the initiation and pro-
gression of PDAC and could be a valuable target in PDAC 
therapy.4,5 Furthermore, it is a juxtacrine cell- cell commu-
nication pathway that positively or negatively affects cellu-
lar proliferation, survival, differentiation, and apoptosis in a 
context- dependent manner. Notch1 is present at the cell sur-
face as a heterodimeric molecule (p120/p200), comprising an 
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Abstract
The marked overexpression of cyclin- dependent kinase 5 (CDK5) or Notch1 recep-
tor, which plays critical roles in pancreatic ductal adenocarcinoma (PDAC) devel-
opment, has been detected in numerous PDAC cell lines and tissues. Although, a 
previous study has demonstrated that CDK5 inhibition disrupts Notch1 functions in 
human umbilical vein endothelial cells, the mechanism underlying Notch1 activa-
tion regulated by CDK5 remains unclear. Herein, we identified a physical interaction 
between CDK5 and Notch1 in PDAC cells, with the Notch1 peptide phosphorylated 
by CDK5/p25 kinase. CDK5 blockade resulted in the profound inhibition of Notch 
signaling. Accordingly, CDK5 inhibition sensitized PDAC cell proliferation and mi-
gration following Notch inhibition. In conclusion, CDK5 positively regulates Notch1 
function via phosphorylation, which in turn promotes cell proliferation and migration. 
The combinational inhibition of CDK5 and Notch signaling may be an effective strat-
egy in the treatment of PDAC.
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extracellular domain (p200) involved in ligand binding and a 
cytoplasmic domain (p120) involved in signal transduction. 
The precursor Notch1 protein (p300) is cleaved into extracel-
lular and cytoplasmic domains in the trans- Golgi network by 
furin. Ligand binding triggers a cascade of prototypic cleav-
age events and finally releases the Notch intracellular domain 
(NICD). Then, the NICD is translocated into the nucleus and 
binds to the DNA- binding protein CBF1, leading to the tran-
scriptional activation of multiple effector genes such as those 
encoding members of the HES/HEY family.6 Although, the 
molecular components of Notch signaling have been well de-
fined, and signaling from the cell surface to the genome is 
simple and linear, the mechanisms regulating Notch activity 
need to be comprehensively elucidated.6
Cyclin- dependent kinase 5 (CDK5) is also known to 
contribute to PDAC formation and progression.7 This 
proline- directed serine/threonine kinase is activated follow-
ing association with either one of two noncyclin activator 
proteins, p35 and p39. The cleavage of p35 and p39 to p25 
and p29, respectively, yields activators with greater stability 
and increased CDK5 kinase activation when compared with 
that of observed with the full- length forms of p35 and p39.7 
CDK5 is mainly activated by p35 or its truncated product, 
p25, and the active CDK5/p25 kinase is present in Golgi 
membranes in neurons.8,9 Although, the role of CDK5 in the 
central system is well characterized, it has been recently as-
sociated with the development and progression of multiple 
cancers, including brain, breast, lung, colon, and pancreatic 
cancer.7,10 Accumulating evidence has implicated CDK5 as 
an important determinant of malignant progression, inva-
sion, and metastasis in PDAC.11,12 CDK5 is widely active, 
and p35 and p39 are significantly overexpressed in PDAC.13 
Thus, both CDK5 and Notch1 are important proteins that af-
fect PDAC cell growth, invasion, and metastasis. In the cur-
rent study, we investigated the crosstalk between CDK5 and 
Notch1 signaling in PDAC cells.
2 |  MATERIALS AND METHODS
2.1 | Cell culture and chemical compounds
Human BxPC- 3 and HPAC PDAC cells were obtained from 
National Infrastructure of Cell Line Resource (Beijing, 
China) and were grown in DMEM (Dulbecco's Modified 
Eagle's medium) supplemented with 10% fetal bovine 
serum (Cat#900- 108, Gemini), 100  units/mL penicillin, 
and 100 mg/mL streptomycin (Cat#15140122, HyClone) at 
37°C in humidified air with 5% CO2. siRNAs and plasmids 
were transfected using Lipofectamine 2000 (Cat#11668030, 
Invitrogen) according to the manufacturer's instructions. 
Roscovitine (Cat#R7772, Sigma) was used to inhibit CDK5 
kinase activity. The γ- secretase inhibitor DAPT (Cat#D5942, 
Sigma) was used to prevent Notch cleavage and nuclear entry. 
The inhibitors were diluted in dimethyl sulfoxide (DMSO), 
which was also used as a control.
2.2 | Co- immunoprecipitation and 
immunoblotting assay
Cells were washed with cold PBS, collected by scraping, and 
lysed in lysis buffer (50  mM Tris- HCl [pH 7.5], 150  mM 
NaCl, 0.3% Nonidet P- 40, and 2  mM EDTA) containing 
protease inhibitor cocktail (Cat#HY- K0011, MCE). Cells 
were lysed on ice for 40 min, followed by centrifugation at 
12000 × g for 40 min at 4°C, and the supernatant was re-
moved. For immunoprecipitaion, 1  mg of protein was in-
cubated with 2  μg of specific antibodies at 4°C overnight. 
Subsequently, 30  μL protein A/G agarose (Cat#sc- 2003, 
Santa Cruz Biotech) was added, and samples were incu-
bated at 4°C for 2  h. Beads were then washed five times 
using the lysis buffer. Between washes, the beads were col-
lected by centrifugation at 1000 × g for 3 min at 4°C. The 
precipitated proteins were eluted from the beads by resus-
pending the beads in 2  ×  protein loading buffer and boil-
ing for 10  min. Immunoblotting was then performed. For 
routine immunoblotting, cells were washed twice with cold 
PBS, then lysed in RIPA buffer. Equal amounts of protein 
were loaded onto SDS– PAGE and transferred onto poly-
vinydene fluoride (PVDF) blotting membranes. The mem-
branes were blocked with 5% fat- free milk then probed with 
indicated antibodies at 4°C. The primary antibodies were as 
follows: anti- Notch1 (Cat#sc- 32756, Santa Cruz Biotech), 
anti- CDK5 (Cat#LS- B353, LifeSpan BioSciences), anti- p35 
(Cat#41304, Signalway), anti- HA (Cat#sc- 7392, Santa Cruz 
Biotech), and anti- β- actin (Cat#66009, Proteintech Group). 
Members were then washed and incubated with anti- rabbit 
or anti- mouse horseradish peroxidase- conjugated anti-
bodies (Cat#SA00001- 1, SA00001- 2, Proteintech Group) 
for 1  h at room temperature. Signals were detected using 
a chemiluminescence Western Blot scanner (ChampGel 
7000, SAGECREATION). Protein levels were normal-
ized to β- actin levels and quantified using ImageJ software. 
Densitometry analyses of the blots for Figure  3 were in 
Figure S2.
2.3 | RNA extraction and expression analysis
Total RNA from HPAC and BxPC- 3 cells that had un-
dergone indicated treatment was isolated using Trizol 
(Cat#15596018, Invitrogen). For reverse transcription and 
polymerase chain reaction (RT- PCR), first- strand cDNA 
was synthesized form 1 μg of total RNA using SuperScript 
Kit (Cat#18091050, Invitrogen) according to the supplier's 
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manual. Quantitative RT- PCR was performed using a 
SYBR® Green Realtime PCR Master Mix (Cat#QPK- 201, 
Toyobo) and an Mx3000P instrument (Stratagene 
Laboratories). The primer sequences for qPCR are listed 
in Table 1.
2.4 | DNA constructs, site- directed 
mutagenesis, and siRNA- mediated 
CDK5 knockdown
Wild- type CDK5 was cloned into the pCDNA3.1 vector. 
Point mutations were established using the Q5 Site- Directed 
Mutagenesis Kit (Cat#E0554, New England Biolabs) with 
primer pairs matching target regions. The following prim-
ers were used for mutagenesis: D144  N forward primer, 
5’- GAAATTGGCTAATTTTGGCCTGG- 3’ and reverse 
primer, 5’- AGCTCCCCATTCCTGTTTATTAG- 3’; and K33 T 
forward primer, 5’- GTGGCTCTGACACGGGTGAGG- 3’ 
and reverse primer, 5’- GATCTCATGAGTCTCCCGG- 3’.
siRNA specific for CDK5 was synthesized by Shanghai 
GenePharma Co., Ltd. (Shanghai, China). The CDK5 siRNA 
sequence was 5’- GGGAGAUCUGCCUACUCAATT- 3’. 
The negative control siRNA (NcRNA) sequence was 
5’- UUCUCCGAACGUGUCACGUTT- 3’.
2.5 | Immunofluorescence
For cells immunostaining, cells were rinsed twice in PBS and 
fixed for 15 min in 4% paraformaldehyde/PBS at room tem-
perature. After rinsing, permeabilization was achieved in 0.4% 
Triton X- 100/PBS for 20 min. Indicated antibodies incubation 
were performed in PBS overnight at 4°C, following blocking 
in 10% serum/PBS for 10 min. After being rinsed in PBS, cells 
were incubated with Alexa Fluor 488- conjugated anti- mouse 
IgG (Cat#R37120, Invitrogen) and Alexa Fluor 594- conjugated 
anti- rabbit IgG (Cat#R37117, Invitrogen) for 1 h at room tem-
perature. Cells were DAPI- treated to stain nuclei and mounted 
with anti- fade medium. Images were captured using a confocal 
laser- scanning microscope (LSM880, Carl Zeiss).
Human pancreatic cancer tissue microarrays were pur-
chased from Xi'an Alena Biotechnology Co., Ltd. of China. 
Following dewaxing, rehydration and antigen retrieval, the 
samples were stained with Notch1 and CDK5 antibodies 
at 4°C overnight. The samples were then incubated with 
Alexa Fluor 488- conjugated anti- rabbit IgG (Cat#R37118, 
Invitrogen) and Alexa Fluor 594- conjugated anti- mouse 
IgG (Cat#R37121, Invitrogen) for 1 h at room temperature. 
Nuclei were conterstained with DAPI. The stained tissues 
were visualized using a confocal laser- scanning microscope 
(LSM880, Carl Zeiss).
2.6 | In vitro kinase assays and mass 
spectrometry
Assays were performed using 100  µM Notch1 peptide 
(LifeTein, Beijing, China) and 7.8 nM CDK5/p25 (Cat#14- 
516- M, Sigma) in 5  mM MOPS (pH 7.2), 5  mM MgCl2, 
1 mM EGTA, 0.4 mM EDTA, 0.25 mM DTT, 50 ng/μL BAS, 
and 100 µM ATP. The reactions were performed for 30 min 
at 32.6°C. Following the kinase assays, the Notch1 peptide 
was subjected to TiO2 affinity chromatography according 
to the manufacturer's manual (GL Sciences, Eindhoven, 
Netherlands). Liquid chromatography- tandem mass spec-
trometry (LC- MS/MS) was performed using a Q Exactive 
mass spectrometer (Thermo Fisher Scientific, USA). The 
peptide- based enzyme activity assay is a highly sensitive and 
convenient method.14
2.7 | Expression and survival analysis using 
GEPIA web tool
The online database Gene Expression Profiling Interactive 
Analysis (GEPIA, http://gepia.cance r- pku.cn/) was used to 
analyze Notch1, CDK5, p35, and p39 RNA sequencing ex-
pression data based on The Cancer Genome Altas (TCGA) 
and the Genotype- Tissue Expression (GTEx) projects.15 The 
overall survival analysis was performed using Kaplan– Meier 
in the GEPIA dataset.
T A B L E  1  Sequences of the primers for qPCR
Gene Forward primers Reverse primers
p35 5’- CCAGAACAACATCACGCACC −3’ 5’- GGGTGAGGGGCTTTCTTGAC −3’
CDK5 5’- GCACAAGAACATCGTCAGGC −3’ 5’- TTGGCCCCAAAGAGGACATC −3’
Notch1 5’- GCAGTTGTGCTCCTGAAGAA −3’ 5’- CGGGCGGCCAGAAAC −3’
Hes1 5’- TGATTTTGGATGCTCTGAAGAAAGATA−3’ 5’- GCTGCAGGTTCCGGAGGT−3’
C- Met 5’- GTAAGTGCCCGAAGTGTA−3’ 5’- TTTCTTGCCATCATTGTC−3’
β- actin 5’- GTGACGTGGACATCCGCAAAGAC−3’ 5’- TCAAGAAAGGGTGTAACGCAACTAA−3’
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2.8 | Cell metabolism viability, 
proliferation, and migration assay
BxPC- 3 and HPAC cells were inoculated in 96- well cul-
ture plates, and cell viability was evaluated by reduction 
of MTT tetrazolium salt [3- (4, 5- dimethylthiazol- 2- yl)- 2, 
5- diphenyltetrazolium bromide] (0.5  mg/ml) by viable 
cells to form purple formazan product after 2 h incuba-
tion. Experiments were performed in triplicate on indi-
cated conditions, and repeated at least three times.
For a colony assay, 1000 cells were plated in six- well 
plates to assess the effect of CDK5 and/or Notch inhibitors 
on colony formation after 10 days of incubation at 37°C in 
5% CO2 incubator.
For a migration assay, HPAC cells were seeded in a six- 
well plate (2  ×  105  cells/well) and incubated for 24  h. A 
scratch was made using a 1- mL pipette tip, followed by treat-
ment of cells with indicated inhibitors. Images were captured 
at 0 and 48 h using an inverted microscope. ImageJ software 
was used to calculate the area of the scratch. Then, the per-
centage of wound closure was calculated and compared with 
that of the control.
2.9 | Statistical analysis
Data are presented as the mean ±standard deviation. 
Comparisons between control and target data sets were per-
formed using independent sample t- tests, with P- values less 
than or equal to 0.05 indicating statistical significance.
3 |  RESULTS
3.1 | Colocalization of CDK5 with Notch1 in 
vivo
To determine the physiological relevance, we examined 
the interaction of CDK5 and Notch1 in vivo using co- 
immunoprecipitation. CDK5, p35, and Notch1 were ex-
pressed in BxPC- 3 and HPAC cells (Figure 1A and B). We 
observed that Notch1 copurified with CDK5 but not with 
the IgG control, and CDK5 copurified with Notch1, dem-
onstrating their specific binding and indicating a physical 
interaction between CDK5 and Notch1 (Figure 1C and D). 
To further determine whether CDK5 and Notch1 colocal-
ize in vivo, immunostaining was performed. Staining with 
F I G U R E  1  CDK5 physically associates with Notch1 in pancreatic cancer cells. The mRNA (A) and protein levels (B) of CDK5, p35, and 
Notch1 were examined in BxPC- 3 and HPAC cells. Cell lysates were immunoprecipitated with anti- CDK5 (C) or anti- Notch1 antibodies (D), 
and immunoblotting was performed with anti- Notch1 and anti- CDK5 antibodies. Normal mouse or rabbit IgGs were used as negative controls. 
Intracellular interactions of CDK5 and Notch1 in BxPC- 3 (E) and HPAC (F) cells were visualized with a confocal microscope. The scale bar is 
25 μM. CDK5, cyclin- dependent kinase 5
   | 3693CHU et al.
CDK5- specific antibodies revealed that endogenous CDK5 
was distributed through both the nucleus and cytoplasm 
of cells. Colocalization of Notch1 and CDK5 in the cyto-
plasm of BxPC- 3 and HPAC cells was observed by yellow 
fluorescence when images of Cy3- stained anti- Notch1 and 
FITC- stained anti- CDK5 immunocomplexes were merged 
(Figure 1E and F).
3.2 | Phosphorylation of Notch1 peptide by 
CDK5 in vitro
To determine the mechanism through which CDK5 regulates 
Notch1 activation, we explored the potential phosphorylation 
of Notch1 by CDK5. We analyzed Notch1 for the presence of 
phosphorylation motifs using the NetPhos 3.1 Server (http://
www.cbs.dtu.dk/servi ces/NetPh os/), which predicts protein 
phosphorylation sites and potential kinase activity. This 
analysis revealed the presence of 29 CDK5 phosphorylation 
sites in human Notch1 with a score greater than 0.5. To deter-
mine whether CDK5 affects the phosphorylation of Notch1, 
we determined whether CDK5 could phosphorylate a Notch1 
peptide (Notch1 2128– 2152, NP_060087.3) containing three 
potential CDK5 phosphorylation sites (Figure  2A). An in 
vitro kinase reaction demonstrated that T2132, S2136, and 
S2141 were CDK5- phosphorylated sites in the Notch1 pep-
tide (Figure  2B, C, and D). In the control experiment, the 
peak of Notch1 peptide was observed at 2424.2 kD (Figure 
S1A) without CDK5/p25 kinase, which shifted to 2504.8 kD 
with CDK5/p25 kinase (Figure S1B), indicating the specific 
kinase activity of CDK5 on the Notch1 peptide.
3.3 | Inhibition of CDK5 activity impairs the 
Notch1 pathway
To investigate whether CDK5 regulates Notch1 cleavage 
and activation, CDK5 kinase activity was inhibited using 
roscovitine, CDK5- specific siRNA, or dominant- negative 
CDK5 (dnCDK5), respectively. The blockade of CDK5 by 
roscovitine markedly inhibited the viability of both BxPC- 3 
and HPAC cells, as assessed by the MTT assay (Figure 3A). 
After pretreatment with the indicated concentration of ros-
covitine for 1 h, levels of the 120 kD cleavage product of 
Notch1 decreased in both cell lines, and full- length Notch1 
only accumulated in HPAC cells (Figure 3B). Furthermore, 
mRNA levels of the downstream Notch target genes, Hes1, 
c- Met, and NFIA, were reduced in HPAC cells treated with 
roscovitine for 6 h when compared with their levels in con-
trol cells, while only the Hes1 mRNA level was decreased in 
BxPC3 cells. Roscovitine did not affect the Notch1 mRNA 
level in either cell line (Figure 3C). Although, CDK5 is the 
primary target of roscovitine, it also inhibits other CDKs, 
such as CDK1, CDK2, CDK7, and CDK9. To determine 
the specific effect of CDK5 blockade on Notch1, we used 
an RNA interference (RNAi) strategy to antagonize CDK5 
F I G U R E  2  Human Notch1 contains putative CDK5 phosphorylation sites and could be phosphorylated by CDK5. (A) The human Notch1 
protein sequence (NP_060087) was analyzed using the Motif Scan program. The scores of three potential CDK5 phosphorylation sites in Notch1 
2128– 2152 residues are shown. (B, C, D) The phosphorylated Notch1 peptides were detected by liquid chromatography- mass spectrometry (LC- 
MS). The phosphorylated S and T residues are indicated by lowercase letters. CDK5, cyclin- dependent kinase 5
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function. Similarly, the Notch1 level was profoundly de-
creased following RNAi knockdown of CDK5 in BxPC- 3 
and HPAC cells (Figure  3D). We further confirmed that 
mRNA levels of the Notch1 target genes Hes1 and c- Met 
were downregulated in CDK5 knockdown cells; however, 
the mRNA level of Notch1 was not altered in either cell line 
(Figure 3E).
To identify whether the regulation of Notch signal-
ing was related to the kinase activity of CDK5, we treated 
HPAC cells with the enforced expression of two dominant- 
negative CDK5 (dnCDK5) proteins with an HA tag. The 
dnCDK5 constructs were D144  N and K33  T kinase- dead 
mutants that abolish the activation of endogenous CDK5 by 
p35 when overexpressed.16 Consistent with results from the 
RNAi strategy, HPAC cells expressing dnCDK5 constructs 
presented significantly reduced levels of the 120 kD cleav-
age product of Notch1, indicating that CDK5 kinase activity 
decreases Notch1 activation (Figure  3F). Furthermore, the 
striking downregulation of the active form of Notch1 (NICD) 
was observed in HPAC cells with knockdown of CDK5, and 
could be restored by exogenous expression CDK5 (Figure 3). 
Collectively, these results from multiple independent exper-
iments confirmed that Notch1 activation is profoundly dis-
rupted in CDK5- inhibited cells.
3.4 | Blockade of CDK5 and Notch 
synergistically inhibits growth and migration
To determine the combined effect of CDK5 and Notch1 
signaling on pancreatic cancer cells, we measured the ef-
fect of blocking CDK5 and/or Notch signaling on cell 
proliferation and migration. DAPT is a γ- secretase inhibi-
tor that inhibits the Notch signaling pathway. As several 
F I G U R E  3  Inhibition of CDK5 attenuates Notch1 signaling. (A) Cells were treated with 10 μM roscovitine. Cell viability was detected 
using the MTT assay. Experiments at all- time points were assayed in triplicate. (B) Cells were treated with indicated roscovitine concentration for 
1 h, and lysates were immunoblotted with Notch1 antibody to detect the full- length (Notch1/p300 kD) and 120 kD cleavage products of Notch1 
(Notch1/p120 kD). (C) The mRNA levels of Notch1 signaling pathway effectors, Hes1, C- Met, NFIA, and Notch1, were detected in BxPC3 and 
HPAC cells. Cells were treated with 10 μM roscovitine for 6 h. (D) Cells were transfected with CDK5- siRNA or negative control- RNA (NC) for 
48 h. Protein levels of CDK5, Notch1 (Notch1/p120 kD), and β- actin were detected. (E) The mRNA levels of CDK5, Notch1, Hes1, and C- Met 
were detected using qRT- PCR analysis. (F) HPAC cells were transiently transfected with CDK5 or CDK5- D144 N or CDK5- K33 T or pCMV 
vector as control (Ctr). HA- tag antibody was used to detect CDK5 or CDK5 mutants. Protein levels of Notch1 (Notch1/p120 kD) and β- actin were 
detected. CDK5, cyclin- dependent kinase 5; qRT- PCR, real- time quantitative reverse transcription- polymerase chain reaction
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references have demonstrated that pharmacologic inhibi-
tion of CDK5 or Notch signaling had the same effect as 
knockdown of CDK512,13,17 or Notch118 with siRNA. Both 
pharmacologic and genetic inhibition mitigated growth in 
pancreatic cancer cells. Here, we used the inhibitors to 
explore the combined effect of CDK5 and Notch1 signal-
ing on pancreatic cancer cells growth. Both DAPT and 
roscovitine significantly inhibited HPAC cell growth 
(Figure  4A) and migration (Figure  4C) when compared 
with that of observed in control (DMSO- treated) cells. 
The combined use of DAPT and roscovitine inhibited cell 
growth and migration to a greater extent than treatment 
with either agent alone (Figure 4A and C). These results 
indicated that CDK5 inhibition sensitized HPAC cells to 
more effectively inhibit cell proliferation and migration 
via Notch inhibition.
3.5 | CDK5 signaling is associated with 
Notch signaling in PDAC
To verify the relevance of CDK5 signaling and Notch sign-
aling in PDAC pathogenesis, we examined the expression 
and interaction between CDK5 and Notch1 in clinical PDAC 
specimens.
Based on the GEPIA database, we observed that Notch1, 
CDK5, p35, and p39 were overexpressed in pancreatic ad-
enocarcinoma (PAAD) samples (Figure  5A). The higher 
Notch1 and p39 expressions correlated with poor overall 
survival (Figure 5B). Consistent with their colocalization in 
HPAC and BxPC3 cells, CDK5 and Notch1 colocalized in 
PDAC specimens (Figure  5C). To investigate the potential 
relationship between Notch and CDK5 signaling pathways in 
patients with PDAC, Gene Set Enrichment Analysis (GSEA) 
F I G U R E  4  Roscovitine and DAPT synergistically inhibit proliferation and migration. HPAC cells were treated with 10 μM roscovitine and/
or 2 μM DAPT. (A) Representative images showing the ability of HPAC cells to form colonies. Scale bar, 5 mm. (n = 3) (B) The histogram shows 
the number of colonies formed. (C) Representative microscopic images presenting the effect of roscovitine and DAPT on the migration of HPAC 
cells. Scale bar, 100 μM. (n = 3) (D) The semi- quantitative image analysis of migration is also presented. (E) The proposed model presenting the 
function and mechanism of Notch1 regulated by CDK5. CDK5 positively regulates Notch1 signaling by phosphorylation, which in turn promotes 
cell proliferation and migration. *p ≤ 0.05. CDK5, cyclin- dependent kinase 5
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using the TCGA pancreatic cancer data set was performed to 
assess Notch/CDK5 signaling. The GSEA outcomes revealed 
that gene signatures of Notch signaling activation were en-
riched in patients with high CDK5 expression and high p35 
expression (Figure 5D), suggesting a positive correlation be-
tween Notch and CDK5 signaling.
4 |  DISCUSSION
In the present study, we unraveled the physical association 
between CDK5 and Notch1 and revealed their colocalization 
in the cytoplasm. During intracellular processing, full- length 
precursor Notch1 is transported to the trans- Golgi apparatus 
and then cleaved into two linked peptides.6 As active CDK5/
p25 kinase is also located in Golgi membranes,8,9 the two 
proteins might colocalize in the Golgi network. The phos-
phorylation of Notch1 by CDK5 could regulate the cleavage 
of Notch1 by furin, as well as the maturation of the Notch1 
receptor.
The inhibition of CDK5 by roscovitine significantly 
reduced the 120 kD cleavage product of Notch1 in both 
BxPC- 3 and HPAC cells, which resulted in the significant ac-
cumulation of full- length Notch1 in HPAC cells (Figure 3A). 
The different regulatory mechanisms of Notch activation 
and heterogeneity in the transcriptional activation of target 
genes in Notch- ON cells might account for this observation.5 
Consistent with a previous study, our results suggest that 
CDK5 has a positive effect on Notch1- dependent signaling.19 
In the previous report, the authors revealed that CDK5 in-
hibition disrupted NICD generation and Notch function.19 
Although, BxPC- 3 and HPAC cells almost have the same 
expression level of CDK5 protein, the full- length of Notch1/
p300 is a little higher in BxPC- 3 (Figure 1B). In the follow-
ing experiments, CDK5 inhibitor, CDK5- siRNA and CDK5 
dominant- negative plasmids were used to explore the spe-
cific role of CDK5 in Notch1 signaling regulation, and the 
results showed that Notch1 activation is profoundly disrupted 
in CDK5- inhibited cells (Figure 3).
The inhibition of CDK5 decreased Notch1 cleavage but 
not Notch1 expression, further downregulating Notch1 sig-
naling (Figure  3). This indicates that Notch1 is regulated 
by CDK5 at the post- transcriptional level. As CDK5 is a 
proline- directed serine/threonine kinase, Notch1 may be 
regulated by CDK5 via phosphorylation. Notch is regulated 
by various post- translational modifications, including phos-
phorylation, during multiple steps in the signaling pathway. 
Phosphorylation occurs at multiple sites within the NICD 
and regulates Notch signaling at different levels, such as 
the maturation and localization of Notch1 in the cell mem-
brane,20 translocation of the NICD into the nucleus,21 the 
formation of a transcript complex and its binding to the pro-
moter of the target genes,22 and the stability of the NICD.23 
Three serine/threonine kinases that interact with Notch1 
have been identified: GSK- 3β, CDK8, and CK2.21,24,25 In 
this study, we demonstrated that T2132, S2136, and S2141 
are CDK5 phosphorylation sites in the Notch1 peptide. 
CDK5 phosphorylates proteins at two consensus sequences: 
(S/T)PX(K/H/R) and PX(S/T)P (where X is any amino 
acid).26 Thus, T2132, S2136, and S2141 are potential can-
didate sites for CDK5 phosphorylation in Notch1 in vivo. 
The future study needs to examine the identified Notch1 
phosphorylation site with full- length Notch1 and the effect 
of these sites mutations on Notch1 signaling regulated by 
CDK5.
High expressions of CDK5, p35, or p39 and hyper- 
activation of CDK5 signaling have been reported in several 
cancers, including breast, ovarian, and colorectal cancer.27 
Inhibition of CDK5 reportedly impairs tumorsphere for-
mation and reduces tumor establishment.28 Based on the 
GEPIA database, we observed that expression levels of 
Notch1, CDK5, p35, and p39 are higher in PDAC tumor tis-
sues than in normal tissues. High expression of Notch1 and 
p39 correlated with poor prognosis and shorter patient sur-
vival in PDAC (Figure 5A and 5B). Collectively, these ob-
servations indicate that CDK5 and Notch1 act as oncogenes 
in PDAC. Although, Notch1 is a target for PDAC therapy, 
and the downregulation of Notch contributes to the inhibi-
tion, apoptosis, and metastasis of PDAC, clinical experience 
with Notch pathway inhibitors remains relatively limited.29 
Currently, several classes of Notch pathway inhibitors, in-
cluding γ- secretase inhibitors (GSIs) and specific receptors 
or antibodies, are in clinical development.29 Despite the 
toxicity and limited therapeutic efficacy in clinical and pre-
clinical studies, GSIs have revealed some clinical benefits; 
for example, the GSI PF- 0308414 reportedly demonstrates 
promising clinical activity in a phase I dose- finding study.30 
Some studies have suggested the combined use of low dose 
GSIs and other drugs to target tumor cells, with the objec-
tives of tolerable toxicity and better clinical responses.31 
F I G U R E  5  High CDK5 and p35 expression positively correlate with Notch signaling. (A) Analysis of differential expression of Notch1, 
CDK5, p35, and p39 in normal and PDAC patients of using GEPIA. Tumor: n = 179; Normal: n = 171. (B) The survival curves of p35 and p39 
were analyzed using GEPIA. (C) Representative double immunofluorescence staining of Notch1 (green) and CDK5 (red) in PDAC. (n = 3) (D) The 
PDAC samples from TCGA database were ranked from low to high CDK5 or p35 expression groups, with quartile as boundary, the first 25% of the 
samples were the low expression group, and the last 75% were the high expression group. Enrichment plots of gene expression signatures for the 
Notch pathway activation was analyzed by GSEA according to CDK5 or p35 mRNA expression levels. CDK5, cyclin- dependent kinase 5; NES, 
normalized enrichment score; FDR, false discovery rate
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Thus, designing rational combinations of therapeutic agents 
to inhibit possible compensatory escape mechanisms could 
be of particular importance. Furthermore, targeting several 
pathways simultaneously may offer considerable benefits. 
Notably, CDK5 inhibitors are already in pharmaceutical 
development owing to the broad protumorigenic role of 
CDK5.7 Therefore, the development of CDK5 and Notch 
as combinational targets for pancreatic cancer could be 
undertaken. Our data showed that the combination of ros-
covitine and DAPT exhibited stronger inhibition on PDAC 
cell proliferation and migration than the inhibition of CDK5 
or Notch function alone (Figure  4A and 4C). It has been 
demonstrated that CDK5 inhibition can sensitize the neo-
vascular endothelium of burgeoning tumors to allow more 
effective anti- angiogenic treatment, such as the inhibition of 
the Dll4/Notch pathway.19 Thus, the combinational inhibi-
tion of Notch and CDK5 is a potential strategy for PDAC 
treatment. This combinational strategy need to be further 
confirmed in xenograft mouse model.
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